On December 26, 2025, the Minister of Health of the Kyrgyz Republic, Kanbek Dosmambetov, held a working meeting with representatives of UN organizations, during which issues related to pharmaceutical provision under the existing Memorandum of Understanding were discussed. This information was provided by the Ministry of Health of the Kyrgyz Republic.
During the meeting, emphasis was placed on the main areas of cooperation in the field of pharmaceutical provision, including the development of a national regulatory system, increasing access to essential medicines, enhancing procurement transparency, and ensuring the resilience of supply chains.
The Minister noted that ensuring fair and sustainable access to quality medical products is one of the key priorities of state health policy and is directly linked to achieving the Sustainable Development Goals, primarily the goal of "Good Health and Well-Being".
Special attention was given to issues of procurement transparency and corruption prevention. Kanbek Dosmambetov emphasized the importance of systemic changes aimed at eliminating unfair practices and effectively utilizing budget funds.
"The state allocates significant funds for the procurement of medicines, and our task is to ensure their transparent and rational use. We are focused on strict control in the procurement sector, cleansing the system of unfair practices, and creating sustainable and honest interactions. We are confident that with the support of our international partners, this cooperation will become systematic and long-term," noted Kanbek Dosmambetov.
Development partners confirmed their readiness to deepen cooperation, including support in procurement according to international standards, supply chain management, digital solutions, pharmacovigilance, and enhancing the institutional capacity of the healthcare system.
As a result of the meeting, the parties agreed to continue joint work on implementing the provisions of the memorandum of understanding with a focus on specific, measurable outcomes aimed at strengthening pharmaceutical security and protecting patient interests. ```
